1

2
Pan Clark, Whelan James P: Modified glp-1 receptor agonists and their pharmacological methods of use. Bayer Pharmaceuticals Corporation, Pan Clark, Whelan James P, sGREENMAN Jeffrey M, March 18, 2004: WO/2004/022004 (79 worldwide citation)

This invention relates to modified GLP-1 receptor agonists comprising a GLP-1 receptor agonist linked to a polyethylene glycol polymer having a molecule weight of greater than 30 kD, and related formulations and dosages and methods of administration thereof for therapeutic purposes are provided. Mor ...


3

4
Chen Yuanwei, O Connor Stephen James, Gunn David, Newcom Jason, Chen Jianqing, Yi Lin, Zhang Hai Jun, Hunyadi Laszlo Matyas, Natero Reina: Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity. Bayer Pharmaceuticals Corporation, Chen Yuanwei, O Connor Stephen James, Gunn David, Newcom Jason, Chen Jianqing, Yi Lin, Zhang Hai Jun, Hunyadi Laszlo Matyas, Natero Reina, GREENMAN Jeffrey M, July 15, 2004: WO/2004/058727 (45 worldwide citation)

This invention relates to substituted 3,5-dihydro-4H-imidazol-4-ones compounds which are useful in the treatment of obesity and obesity-related disorders, and as weight-loss and weight-control agents. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions com ...


5
Wood Jill E, Chen Yuanwei, Hart Barry, Yi Lin, Chen Jianqing: Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders. Bayer Pharmaceuticals Corporation, Wood Jill E, Chen Yuanwei, Hart Barry, Yi Lin, Chen Jianqing, GREENMAN Jeffrey M, May 13, 2004: WO/2004/039359 (43 worldwide citation)

A method of treating hyper-proliferative disorders comprising the administration to a patient in need thereof of an effective amount of a compound of Formula (I) wherein R is halo or CF3; n is 0 or 1; R1 is selected independently in each instance from the group consisting of halo, (C1-C3)alkoxy, and ...


6

7
Scott William J, Dumas Jacques, Boyer Stephen, Lee Wendy, Chen Yuanwei, Phillips Barton, Verma Sharad, Chen Jianqing, Chen Zhi, Fan Jianmei, Raudenbush Brian, Redman Aniko, Yi Lin, Zhu Qingming: Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders. Bayer Pharmaceuticals Corporation, Scott William J, Dumas Jacques, Boyer Stephen, Lee Wendy, Chen Yuanwei, Phillips Barton, Verma Sharad, Chen Jianqing, Chen Zhi, Fan Jianmei, Raudenbush Brian, Redman Aniko, Yi Lin, Zhu Qingming, TRAVERSO Richard J, September 16, 2004: WO/2004/078747 (36 worldwide citation)

This invention relates to novel diaryl ureas of Formula (I), pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper­proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.


8
Shimada Mitsuyuki, Murata Toshiki, Fuchikami Kinji, Tsujishita Hideki, Omori Naoki, Kato Issei, Miura Mami, Urbahns Klaus, Gantner Florian, Bacon Kevin: Fused azole-pyrimidine derivatives. Bayer Pharmaceuticals Corporation, Shimada Mitsuyuki, Murata Toshiki, Fuchikami Kinji, Tsujishita Hideki, Omori Naoki, Kato Issei, Miura Mami, Urbahns Klaus, Gantner Florian, Bacon Kevin, BAYER PHARMACEUTICALS CORPORATION, April 8, 2004: WO/2004/029055 (34 worldwide citation)

The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (P13K) inhibition, especia ...


9
Clairmont Kevin, Lumb Kevin, Whelan James: (gip) Receptor agonists and their pharmacological methods of use. Bayer Pharmaceuticals Corporation, Clairmont Kevin, Lumb Kevin, Whelan James, GREENMAN Jeffrey M, November 16, 2006: WO/2006/121904 (33 worldwide citation)

This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the GIP receptor. The peptides of the present invention provide a new therapy for pa ...


10
Jacques Dumas, Uday Khire, Timothy B Lowinger, Bernard Riedl, William J Scott, Roger A Smith, Jill E Wood, Holia Hatoum Mokdad, Jeffrey Johnson, Aniko Redman, Robert Sibley: Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas. Bayer Pharmaceuticals Corporation, Millen White Zelano & Branigan P C, February 12, 2008: US07329670 (31 worldwide citation)

The compounds are aryl and heteroaryl substituted heterocyclic ureas of the formula A—NH—C(O)—NH—B where A is the aryl or hetaryl substituted heterocyclic group and B is an aryl or heteroaryl moiety. The compounds inhibit raf kinase and are useful in the treatment of RAF kinase mediated diseases.